Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded at StockNews.com

StockNews.com upgraded shares of Oramed Pharmaceuticals (NASDAQ:ORMP) from a sell rating to a hold rating in a research report released on Friday.

Separately, HC Wainwright restated a “neutral” rating on shares of Oramed Pharmaceuticals in a report on Monday, September 9th.

Oramed Pharmaceuticals Stock Up 0.4 %

Shares of ORMP stock opened at $2.37 on Friday. The firm has a market capitalization of $95.54 million, a price-to-earnings ratio of 21.55 and a beta of 1.70. Oramed Pharmaceuticals has a 12-month low of $2.00 and a 12-month high of $3.67. The firm has a fifty day moving average of $2.37 and a 200-day moving average of $2.40.

Institutional Investors Weigh In On Oramed Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. XTX Topco Ltd bought a new position in Oramed Pharmaceuticals in the second quarter valued at $40,000. Dimensional Fund Advisors LP grew its stake in Oramed Pharmaceuticals by 52.1% in the second quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock valued at $81,000 after purchasing an additional 10,774 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Oramed Pharmaceuticals during the 3rd quarter worth approximately $272,000. Renaissance Technologies LLC raised its stake in shares of Oramed Pharmaceuticals by 89.0% during the 2nd quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock worth $593,000 after purchasing an additional 108,700 shares in the last quarter. Finally, Murchinson Ltd. grew its stake in shares of Oramed Pharmaceuticals by 23.2% in the second quarter. Murchinson Ltd. now owns 1,699,990 shares of the biotechnology company’s stock valued at $4,369,000 after buying an additional 320,495 shares in the last quarter. Institutional investors and hedge funds own 12.73% of the company’s stock.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.